US-based clinical research organisation (CRO) TKL Research has raised its profile in the European market by taking an unspecified equity position in proinnovera, a full-service CRO with headquarters in Münster, Germany. No financial details were disclosed.

According to president and chief executive officer Jon Anderson, having a European office in Germany will build on TLK’s past successes conducting clinical studies in the region and significantly enhances its capacity to cater for US-based sponsors seeking trial services in Europe.

“We will be better established in Europe, have a solid understanding of European sites, offer a dynamic network of medical specialists and hospitals and, as with our US operations, apply this expertise to accelerate patient enrolment,” Anderson said.

TKL cites its reputation for reducing trial timelines by taking responsibility for enrolment and site selection as an important factor in its decision “to move forward” with proinnovera.

Both organisations “excel at enrolment-driven trials”, noted Robert Reardon, executive vice president and chief operating officer of TKL. “Both are committed to quality Phase I-IV clinical research, work closely with sponsors to help evaluate sites’ capabilities, and deliver subjects ahead of schedule. This similar approach to clinical trials will provide our clients with seamless study management and expanded capabilities.”

TKL offers a full range of Phase I-IV services in a number of enrolment-driven therapeutic areas, including dermatology, allergies/respiratory conditions, diabetes, gastroenterology and women’s health. Its German partner’s expertise spans dermatology, pain management, allergy/respiratory, oncology and vaccines.